AR117715A1 - Interferón hiperglicosilado con inmunogenicidad reducida - Google Patents
Interferón hiperglicosilado con inmunogenicidad reducidaInfo
- Publication number
- AR117715A1 AR117715A1 ARP190103715A ARP190103715A AR117715A1 AR 117715 A1 AR117715 A1 AR 117715A1 AR P190103715 A ARP190103715 A AR P190103715A AR P190103715 A ARP190103715 A AR P190103715A AR 117715 A1 AR117715 A1 AR 117715A1
- Authority
- AR
- Argentina
- Prior art keywords
- interferon
- reduced immunogenicity
- hyperglycosylated
- nucleic acid
- acid molecule
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 7
- 108010050904 Interferons Proteins 0.000 title abstract 7
- 229940079322 interferon Drugs 0.000 title abstract 7
- 230000005847 immunogenicity Effects 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 238000006467 substitution reaction Methods 0.000 abstract 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract 1
- 208000006154 Chronic hepatitis C Diseases 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente describe un interferón hiperglicosilado con inmunogenicidad reducida y mayor estabilidad. Además, se describe una molécula de ácido nucleico que codifica para dicho interferón; una célula de expresión de proteínas recombinantes que comprende dicha molécula de ácido nucleico que codifica para dicho interferón modificado; donde dicha célula de expresión de proteínas recombinantes comprende un plásmido o vector que contiene dicha molécula de ácido nucleico. También se describe una formulación farmacéutica que comprende el interferón hiperglicosilado con inmunogenicidad reducida. Reivindicación 1: Un interferón hiperglicosilado con inmunogenicidad reducida caracterizado porque comprende la sustitución de al menos 5 aminoácidos de alguna de las posiciones seleccionadas del conjunto comprendido por: 23, 31, 61, 79, 80, 131, 142, 137, 161 y 171; donde dicha sustitución comprende el cambio del aminoácido de dicha posición por alanina o glicina. Reivindicación 23: El uso del interferón de las reivindicaciones 1 - 9 para el tratamiento de enfermedades seleccionadas del conjunto comprendido por: hepatitis B crónica, hepatitis C crónica.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
| JP2022537837A JP2023514659A (ja) | 2019-12-17 | 2020-12-16 | 免疫原性が低下した修飾インターフェロン－アルファ－２ |
| EP20901063.6A EP4076504A4 (en) | 2019-12-17 | 2020-12-16 | MODIFIED INTERFERON-ALPHA-2 WITH REDUCED IMMUNOGENERICITY |
| MX2022007546A MX2022007546A (es) | 2019-12-17 | 2020-12-16 | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. |
| US17/783,948 US20230127506A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
| PCT/US2020/065246 WO2021126929A1 (en) | 2019-12-17 | 2020-12-16 | Modified interferon-alpha-2 having reduced immunogenicity |
| BR112022011975A BR112022011975A2 (pt) | 2019-12-17 | 2020-12-16 | Polipeptídeo de interferon-¿2 modificado, polipeptídeo gmop-interferon-¿2 modificado, ácido nucleico, plasmídeo, vetor, linha de célula, método para purificação do polipeptídeo de interferon-¿2 modificado, composição farmacêutica, método para uso de um ou mais dos polipeptídeos de interferon-¿2 modificados e método para tratar uma condição médica em um indivíduo |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117715A1 true AR117715A1 (es) | 2021-08-25 |
Family
ID=76478524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190103715A AR117715A1 (es) | 2019-12-17 | 2019-12-17 | Interferón hiperglicosilado con inmunogenicidad reducida |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230127506A1 (es) |
| EP (1) | EP4076504A4 (es) |
| JP (1) | JP2023514659A (es) |
| AR (1) | AR117715A1 (es) |
| BR (1) | BR112022011975A2 (es) |
| MX (1) | MX2022007546A (es) |
| WO (1) | WO2021126929A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
| US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
| WO2024238415A1 (en) | 2023-05-12 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Interferon receptor antagonists and uses thereof |
| CN116814595B (zh) * | 2023-08-30 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种腺苷脱氨酶突变体及其固定化 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060062761A1 (en) * | 2001-03-02 | 2006-03-23 | Carr Francis J | Modified interferon alpha with reduced immunogenicity |
| WO2006020580A2 (en) * | 2004-08-09 | 2006-02-23 | Alios Biopharma Inc. | Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| KR20080026135A (ko) * | 2005-06-03 | 2008-03-24 | 암브룩스, 인코포레이티드 | 개선된 인간 인터페론 분자 및 이의 용도 |
| EP2476428B1 (en) * | 2005-06-29 | 2013-08-21 | Yeda Research and Development Co. Ltd. | Recombinant interferon alpha 2 (IFN alpha 2) mutants |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| US10544199B2 (en) * | 2014-10-29 | 2020-01-28 | Teva Pharmaceuticals Australia Pty Ltd | Interferon alpha 2B variants |
| AR102120A1 (es) * | 2015-09-29 | 2017-02-08 | Univ Nac Del Litoral | Interferón modificado con inmunogenicidad reducida |
| CN112105632A (zh) * | 2018-01-24 | 2020-12-18 | 北京智康博药肿瘤医学研究有限公司 | 细胞因子融合蛋白 |
-
2019
- 2019-12-17 AR ARP190103715A patent/AR117715A1/es unknown
-
2020
- 2020-12-16 MX MX2022007546A patent/MX2022007546A/es unknown
- 2020-12-16 BR BR112022011975A patent/BR112022011975A2/pt unknown
- 2020-12-16 US US17/783,948 patent/US20230127506A1/en active Pending
- 2020-12-16 EP EP20901063.6A patent/EP4076504A4/en active Pending
- 2020-12-16 WO PCT/US2020/065246 patent/WO2021126929A1/en unknown
- 2020-12-16 JP JP2022537837A patent/JP2023514659A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022011975A2 (pt) | 2022-08-30 |
| EP4076504A4 (en) | 2024-04-10 |
| JP2023514659A (ja) | 2023-04-07 |
| WO2021126929A1 (en) | 2021-06-24 |
| EP4076504A1 (en) | 2022-10-26 |
| US20230127506A1 (en) | 2023-04-27 |
| MX2022007546A (es) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117715A1 (es) | Interferón hiperglicosilado con inmunogenicidad reducida | |
| EA201892671A1 (ru) | Пегилированный свиной интерферон и способы его применения | |
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение | |
| PE20211469A1 (es) | Proteinas f de prefusion del vrs estabilizadas | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| BR112018073909A2 (pt) | proteínas klotho recombinantes terapêuticas e composições e métodos envolvendo as mesmas | |
| SI3079715T1 (en) | A mixture of peptides | |
| DK2251353T3 (da) | Homogene fremstillinger af IL-29 | |
| AR087227A1 (es) | CONJUGADO DE INTERFERON a CON POLIETILENGLICOL | |
| IL288541B (en) | Vaccine against rsv | |
| AR058567A1 (es) | Formulaciones de proteinas estables | |
| CL2019003409A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| MX2021013743A (es) | Subunidad s1 modificada de la proteina de espicula de coronavirus. | |
| CL2021001571A1 (es) | Ácido ribonucleico (arn) que codifica para una proteína | |
| HRP20191965T1 (hr) | Stabilizirani polipeptidi faktora rasta slični inzulinu | |
| BR112021023957A2 (pt) | Peptídeos | |
| BR112021012240A2 (pt) | Terapia de gene-célula-tronco hematopoiética para síndrome wiskott-aldrich | |
| BR112022010321A2 (pt) | Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase | |
| CA2692358A1 (en) | Recombinant human interferon-like proteins | |
| HRP20110430T1 (hr) | Fsh glikozilacijski mutant | |
| SA521431197B1 (ar) | منتج دوائي للعلاج بالإنزيم لعلاج البيلة الهوموسيستينية (اضطراب في الهوموسيستين) | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| RU2016135003A (ru) | Новые виды лечения | |
| JP2020516322A5 (es) | ||
| AR123187A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer |